Stella’s US website illustrates menopause care with example combinations of medicines, behavioral support and other approaches. Some examples contain progesterone capsules; another places a vaginal estrogen cream beside a broader hormone plan. Those illustrations can show the range of conversations available without telling a reader to reproduce any particular combination.

This September 29, 2026 review examines the US clinic and its FAQ. It separates the job of each treatment from the service’s examples and distinguishes the medical visit from app-based support. It does not assess a patient’s symptoms, verify a selected prescription or apply the terms of a different country’s Stella service.

Editorial illustration: two consultation chairs and a notebook on a side table.
Stella menopause progesterone review: sample plans describe possibilities, not your prescription — bring the unanswered questions into the appropriate professional conversation.

A sample combination needs more than a list of ingredients

The US care page shows examples involving estrogen gel with progesterone capsules and another involving estrogen spray, capsules and vaginal cream. These are published illustrations, not a formulary proving that every person receives all those components. The page also includes nonhormonal approaches.

The relevant question is why each item appears in the proposed plan. One component may address a different concern from another. Pandia Health’s review examines a catalog whose neighboring entries can create a similar impression. Neither a catalog nor an example plan identifies the correct combination for a reader or establishes that an additional product supplies additional benefit.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
A sample combination needs more than a list of ingredients — keep the exact product identity and its complete label together.

Systemic and local treatment can be discussed without confusing their goals

ACOG’s guidance distinguishes systemic estrogen exposure from local vaginal treatment. Stella’s example containing both types does not explain a universal need for that combination; the clinician would need to identify the intended purpose of each actual prescription. The word estrogen should not conceal whether separate products are addressing separate concerns.

The systemic-estrogen guide frames the protective-role question, while the local-vaginal-treatment guide examines a different exposure context. Reading them together does not create a treatment sequence. It helps a patient ask why a medicine is being considered and which part of the proposed care its evidence supports.

The local-therapy exception has an evidence limit

The 2020 NAMS consensus abstract says a progestogen is not indicated when low-dose vaginal estrogen is used, while noting that endometrial safety had not been assessed in trials beyond one year. It also identifies insufficient safety evidence in women with breast cancer for the treatments discussed. These qualifications matter alongside the headline distinction.

That statement does not authenticate an unidentified cream in Stella’s example or advise changing another prescribed medicine. A full discussion needs the exact product, other hormone exposure and relevant history. The review can identify why the question arises, but it cannot resolve the person-specific balance from a sample displayed on a website.

Editorial illustration: an open reference book, a magnifying glass and a document.
The local-therapy exception has an evidence limit — follow the source behind a claim as well as the advertised description.

The US service range is not a medical eligibility test

The US FAQ gives an age range of 35–70 for the service and describes appointments with clinicians and prescriptions through a preferred pharmacy. Those are program descriptions; age within that range does not establish that hormone therapy or progesterone is appropriate. The page is not evidence of access through Stella’s UK arrangements.

The reviewed records also do not identify a manufacturer or a complete ingredient list for the example capsules. Wisp’s review considers another service whose medication menu needs more precise identification. A brand’s ability to discuss menopause treatment should not be mistaken for confirmed supply of a particular product in every clinical circumstance. A service age range also says nothing about the details of a prior operation. Those clinical facts need their own explanation rather than being inferred from enrollment conditions.

An app can support the plan without owning the prescription

Stella’s care description includes behavioral and lifestyle support, while the FAQ explains access to its app and coaching. These features are separate from a clinician’s prescribing assessment. A sleep exercise, class or coaching conversation does not establish adequate endometrial protection or answer a medicine’s allergy question.

The patient needs to know which contact handles what kind of concern. The reviewed offer does not guarantee unlimited medical appointments merely because a support feature remains available. Keeping those responsibilities explicit also prevents a general wellbeing goal from replacing the specific reason progesterone might be included in a treatment plan.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
An app can support the plan without owning the prescription — keep the product information and the route for asking a question in the same comparison.

The appointment and the pharmacy have separate prices

The FAQ lists a $200 initial consultation and $90 follow-up for self-pay care. It also reports an average $45 copayment for insured visits. An average is not a quote for a particular plan, and it does not establish payment for the medicine sent to the preferred pharmacy.

A comparison should preserve those separate units. No complete progesterone package, selected insurance benefit or pharmacy price was verified here. The reviewed pages also leave detailed cancellation and refund outcomes unresolved. A useful estimate would state the actual appointment, the applicable benefits, any extra professional work and the separately dispensed medicines rather than present the reported average as the entire cost of care.

A new concern should not be forced into the sample plan

The clinic page emphasizes individual care, but its examples cannot determine the meaning of new bleeding or another unexpected change. ACOG recommends assessment of abnormal bleeding and bleeding after menopause. The bleeding-and-treatment guide keeps that responsibility with a professional rather than an online combination diagram.

Stella’s public material supports a service comparison based on clinical visits, pharmacy separation and supplementary support. It does not establish that a sample capsule-and-estrogen plan fits the reader’s history or will produce the advertised relief. The stronger endpoint is an understandable explanation of each proposed component and a clear route back to the appropriate clinical team.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. Stella: US virtual menopause clinicUS provider clinical service and example plans; examples do not establish a universal oral preparation or individual outcome · Checked 2026-09-29
  2. ACOG: Hormone Therapy for MenopauseUS specialty patient guidance; systemic and local exposure, treatment goals and clinical assessment, no personal regimen · Checked 2026-09-29
  3. North American Menopause Society: 2020 Genitourinary Syndrome of Menopause position statementPublished professional consensus abstract only; low-dose vaginal therapy distinction, lack of endometrial trials beyond one year and breast-cancer evidence limits · Checked 2026-09-29
  4. Stella US: frequently asked questionsDated US provider age range, visit fees, pharmacy and coaching scope; no exact capsule ingredients, guaranteed reimbursement or UK offer inferred · Checked 2026-09-28
  5. ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29
Read our editorial method →